불임 치료제 시장 보고서 : 약물 종류별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별(2025-2033년)

The global infertility drugs market size reached USD 4.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.3 Billion by 2033, exhibiting a growth rate (CAGR) of 4.49% during 2025-2033. Increasing infertility rates, advancements in assisted reproductive technologies (ART), supportive government initiatives, rising healthcare expenditure, new pharmaceutical developments, availability of insurance coverage, and the proliferation of fertility clinics are some of the factors accelerating the market growth.

Infertility drugs refer to various medications used to treat infertility and enhance the reproductive health of an individual. They are either injected or taken orally. Some commonly used infertility drugs include gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, ovulatory stimulants, dopamine agonists, and tricyclic antidepressants. They work by stimulating ovulation and follicle development of the ovary in women, whereas they help restore testosterone levels and improve the quality of sperm in men to bring about pregnancy. In recent years, infertility drugs have gained traction among couples who are unable to conceive.

Infertility Drugs Market Trends:

Infertility drugs assist in enhancing the chances of pregnancy in couples by restoring the ability of an individual to contribute to conception. As a result, the rising incidences of infertility and miscarriage represents the primary factor driving the market growth. Besides this, several favorable initiatives undertaken by governments of various countries to spread awareness regarding the available treatment options are catalyzing the demand for infertility drugs. Additionally, there has been a significant increase in the prevalence of chronic diseases, such as cancer, obesity, diabetes, thyroid, polycystic ovarian syndrome (PCOS), and menopausal disorders, on account of hectic work schedules, accompanying stress, and lifestyle changes. Along with this, the declining fertility rates due to delayed pregnancies, late marriages, and unhealthy habits, such as excessive consumption of alcohol, drugs, and smoking, are accelerating the product adoption rates. Furthermore, several key players are engaging in research and development (R&D) activities to launch innovative infertility drugs with enhanced efficacy, lower dosage requirements, and fewer side effects. Moreover, the increasing public funding for developing these drugs and faster drug approvals from various regulatory bodies are propelling the market growth. Other factors, including the escalating demand for generic medicines, improving healthcare infrastructure, rising consumer expenditure capacities, rapid urbanization, and technological advancements, are also providing a positive thrust to the market growth.

Key Market Segmentation:

Breakup by Drug Class:

• Gonadotropin
• Aromatase Inhibitors
• Selective Estrogen Receptor Modulators (SERMs)
• Biguanides
• Others

Breakup by Route of Administration:

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Others

Breakup by End User:

• Male
• Female

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex.

Key Questions Answered in This Report

• 1.How big is the infertility drugs market?
• 2.What is the future outlook of infertility drugs market?
• 3.What are the key factors driving the infertility drugs market?
• 4.Which region accounts for the largest infertility drugs market share?
• 5.Which are the leading companies in the global infertility drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Infertility Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Gonadotropin
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Aromatase Inhibitors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Selective Estrogen Receptor Modulators (SERMs)
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Biguanides
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Oral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Intravenous
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Subcutaneous
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Intramuscular
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by End User

• 9.1 Male
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Female
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Bayer AG
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Ferring Pharmaceuticals
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Livzon Pharmaceutical Group Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Mankind Pharma
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Merck & Co. Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Merck KGaA
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Novartis AG
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Pfizer Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Sanofi S.A.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Theramex
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio